A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

  • Interventional
  • Recruiting
  • NCT04394650
Eligibility Details Visit Clinicaltrials.gov

A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         1. Age ≥ 18 years.

         2. Signed written informed consent prior to any study procedure.

         3. Relapsed and/or refractory multiple myeloma (MM). Subjects must have received at least 3 prior antimyeloma treatment regimens. Subjects must have documented progressive disease during or within 12 months of completing treatment with the last anti-myeloma treatment regimen before study entry. Also, subjects with documented evidence of progressive disease within the previous 6 months and who are refractory or nonresponsive to their most recent anti-myeloma treatment regimen afterwards will be also eligible.

             Subjects must have previously received all of the following therapies:

             1. Autologous stem cell transplant

             2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or combination

             3. Anti-CD38 (eg, daratumumab), either alone or combination

         4. Measurable disease

         5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

         6. Adequate organ function

        Exclusion Criteria:

         1. Known active or history of central nervous system (CNS) involvement of MM

         2. Active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis

         3. Prior treatment with CAR T-cell or another genetically modified T-cell therapy

         4. Prior treatment with investigational therapy directed at BCMA

         5. Uncontrolled or active infection

         6. Active autoimmune disease requiring immunosuppressive therapy

         7. History or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

At a Glance

National Government IDNCT04394650

IRB#IRB20-0068

Lead SponsorJuno Therapeutics, a Subsidiary of Celgene

Lead PhysicianBenjamin Derman

Collaborator(s)N/A

EligibilityAll
18 Years and up
Recruiting